Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1919E atezolizumab added to paclitaxel + bevacizumab for HR-positive/HER2-negative advanced breast cancer
jRCT2031200335Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Paclitaxel + bevacizumab with Paclitaxel + bevacizumab + atezolizumab (2 arms). Primary endpoint: Progression-free survival. Started Feb 2021; status: completed.
02
Drugs
atezolizumabpaclitaxelbevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031200335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200335.